Abbott’s Branded Drug Spin-off Will Boost Profile Of Diversified Device Biz
This article was originally published in The Gray Sheet
Executive Summary
Abbott’s planned spin-off of its branded pharmaceuticals business will raise the profile of its remaining diversified device and diagnostics business while isolating certain long-term risks, including generic drug competition.